Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01492673
Title Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan-Kettering Cancer Center

Ewing sarcoma of bone

extraosseous Ewing sarcoma



Bevacizumab + Cyclophosphamide + Topotecan

Age Groups: adult | child
Covered Countries USA | CAN

No variant requirements are available.